Raymond James analyst Rahul Sarugaser initiated coverage of Fusion Pharmaceuticals with an Outperform rating and $13 price target. Raymond James believes radiotherapeutics are on the verge of an inflection in the broader oncology landscape, and have the potential to become a crucial new pillar of cancer treatment, the analyst tells investors in a research note. The Pluvicto-refractory mCRPC population could drive a $500M/year peak sales opportunity for Fusion, the firm argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FUSN:
- Fusion Pharmaceuticals files to sell 4.78M common shares for holders
- Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- These 2 “Strong Buy” Penny Stocks Could Surge 200% (or More), Says Wedbush
- Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates
- Fusion to open radiopharmaceutical manufacturing facility